BioNTech、Moderna挫逾8% 特朗普官員擬將25名兒童死亡歸咎於新冠疫苗
美國《華盛頓郵報》報道,特朗普政府計劃將25名兒童死亡案例歸咎於新冠疫苗,消息拖累疫苗製造商股價下挫。BioNTech(BNTX.US)挫9%;Moderna(MRNA.US)跌8%;輝瑞(PFE.US)跌3%。
Moderna及輝瑞在美國銷售新冠疫苗,新冠疫苗幾乎是Moderna唯一的收入來源,而輝瑞則擁有較多元化的產品組合。
此外,消息指出,美國食品及藥物管理局(FDA)上月已收緊疫苗的適用範圍,由原先開放予6個月以上人士,改為僅限高風險人群接種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.